Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human papillomavirus type 16 recombinant adenoviral vector vaccine
- Development stage
- Unknown
- Lead developer
- Pukang Biotechnology
- Modality
- Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The human papillomavirus type 16 recombinant adenoviral vector vaccine is a therapeutic vaccine candidate developed by Zhejiang Pukang Biotechnology Co., Ltd. for the treatment of persistent HPV16 infection and cervical intraepithelial neoplasia (CIN). The vaccine utilizes a recombinant adenoviral vector to deliver genetic sequences encoding the HPV16 E6 and E7 oncoproteins. Unlike prophylactic HPV vaccines that induce neutralizing antibodies to prevent viral entry, this therapeutic approach aims to stimulate a robust cellular immune response, specifically CD8+ cytotoxic T lymphocytes, to recognize and eliminate cells already expressing these viral proteins. This mechanism is intended to clear persistent infections and reverse precancerous lesions, potentially preventing progression to cervical cancer.
- Other names
- therapeutic human papillomavirus type 16 recombinant adenoviral vector vaccine
02
Targets
HPV16 E6 oncoproteinHPV16 E7 (Human papillomavirus 16 E7 protein)
Beyond the preview
Go deeper on human papillomavirus type 16 recombinant adenoviral vector vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human papillomavirus type 16 recombinant adenoviral vector vaccine.